Elsa Science
Financials
Estimates*
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | <1m | <1m | <1m |
% growth | - | 407 % | (47 %) | 641 % | (88 %) | 23 % |
EBITDA | - | - | (<1m) | (1.2m) | (2.0m) | - |
% EBITDA margin | - | - | (1585 %) | (371 %) | (4896 %) | - |
Profit | <1m | (<1m) | (<1m) | (1.2m) | (2.0m) | - |
% profit margin | 59 % | (336 %) | (1587 %) | (371 %) | (4905 %) | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$700k | Seed | ||
$335k | Grant | ||
$220k | Grant | ||
$2.2m | Seed | ||
* | SEK37.8m | Seed | |
Total Funding | $8.0m |
Related Content
Recent News about Elsa Science
EditElsa Science is a digital health company focused on providing educational and motivational support for individuals diagnosed with Rheumatoid Arthritis (RA). The company operates in the healthcare technology market, targeting patients who seek to better manage their chronic condition. Elsa Science's primary product is a mobile application that offers personalized plans, symptom tracking, and medication reminders, all based on scientific research. The app aims to empower users by giving them the tools to monitor their symptoms, stay informed about their condition, and actively participate in their treatment plans. The business model is likely subscription-based, generating revenue from users who pay for premium features and services. Elsa Science serves a niche market of RA patients, providing them with a comprehensive solution to improve their quality of life.
Keywords: Rheumatoid Arthritis, digital health, symptom tracking, personalized plans, medication reminders, chronic condition, patient empowerment, healthcare technology, science-based, subscription model.